BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.

News BrightGene Bio-Medical Technology Co., Ltd.

Equities

688166

CNE100003PR1

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
37.83 ^CNY	+0.91%		+8.61%	+8.09%

May. 07	China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7%	MT
May. 07	BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3%	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

China Shares Rise as Property Market Gets Relief; BrightGene Jumps 7%	May. 07	MT
BrightGene to Sell 500 Million Yuan Shares to Actual Controller; Shares Up 3%	May. 07	MT
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 27	CI
Tranche Update on BrightGene Bio-Medical Technology Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	Apr. 01	CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 25	CI
BrightGene Bio-Medical Technology Co., Ltd. announces an Equity Buyback for CNY 20 million worth of its shares.	Feb. 06	CI
BrightGene Bio-Medical Technology Co., Ltd. authorizes a Buyback Plan.	Feb. 05	CI
Oralead Pharma announced that it has received funding from HighLight Capital, Shenzhen Qianhai BangQin Investment Co., Ltd., BrightGene Bio-Medical Technology Co., Ltd., Shenyang Borui Pharmaceutical Co., Ltd.	Jan. 28	CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Chinese Regulator Issues Warning Against BrightGene Bio-Medical Chairman Over Weight Loss Claims	23-10-18	MT
Kanghui Pharma Denies Speculations of Unit’s Involvement in Production of Weight-Loss Drugs	23-10-17	MT
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
BrightGene Bio-Medical Technology's Unit Gets Hospital's Approval for Diabetes Drug Trial	23-07-27	MT
Chinese Drug Regulator Certifies Two Drugs of BrightGene's Unit	23-07-06	MT
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
BrightGene Bio-Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
BrightGene Bio-Medical to Hike Investment in API Production Project to 500 Million Yuan	23-02-08	MT
Xinchuang Biomedical Technology Subsidiary Gets Nod to Hold Anti-Diabetes Drug Trial	22-12-30	MT
BrightGene Bio-Medical Technology Co., Ltd. announced that it has received CNY 226.613082 million in funding from Horizon Asset Management Co. Ltd., Shanghai Leitu Asset Management Co., Ltd. and other investors	22-11-20	CI
BrightGene Bio-Medical Technology Unit Gets Regulatory Approval For Anti-Inflammatory Drug Ingredient	22-11-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BrightGene Bio-Medical Technology Co., Ltd.

Equities

688166

CNE100003PR1

Summary

Filters